Proactiveinvestors recommends
Stocktube video
13/02/2012

Immupharma CEO says its flagship product, Lupuzor, has great potential

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: IMM
Latest Price: 63.50p  (-0.98% Descending)
52-week High: 100.00p
52-week Low: 57.00p
Market Cap: 51.77M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmuPharma PLC
www.immupharma.com

ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.

Full ImmuPharma PLC profile here
Is IMM a Buy, Sell or Hold?Get your FREE analysis of IMM
Pdf

ImmuPharma to update on Lupuzor trials once Cephalon's takeover is completed

30th Sep 2011, 8:23 am by Ian Lyall The rights for IPP-204106 were obtained via a unique research collaboration with the Centre National de la Recherche Scientifique, France's leading scientific research organisation.

ImmuPharma (LON:IMM) said this morning it will update on the progress of the pivotal study on lead product Lupuzor once the acquisition of partner Cephalon is completed.

The American biotechnology group is in the throes of being taken over by the generic drug-maker Teva, throwing into doubt its research programmes.

Lupuzor is a potentially blockbuster treatment for the autoimmune disease Lupus, which is in phase IIb trials in the US and Europe.

The data compiled from this research will be part of the package submitted to America’s Food & Drug Administration and other regulatory authorities for approval.  

Benlysta, a rival product launched by GlaxoSmithKline and Human Genome Sciences (GSK-HGS), has underlined the market potential of the treatments in this area of medicine.

Peak sales of Benlysta are estimated to be $4 billion, but with 1.5 million sufferers in the G7 alone, there is plenty of room for a rival such as Lupuzor.

In parallel, the group is also developing a cancer drug called IPP-204106, which is moving into phase I/IIa trials.

The rights for this compound were obtained via a unique research collaboration with the Centre National de la Recherche Scientifique, France's leading scientific research organisation.

The update was contained in the company’s interim results statement, which revealed the ImmuPharma is in a strong financial position with around £14 million in the bank.

The company posted an operating loss of £1.6 million, down from £2.5 million this time last year.

Chief executive Dimitri Dimitriou said: "The first half of 2011 has seen ImmuPharma build on the success of 2010 with Cephalon, our licensee for Lupuzor, moving ahead with a large trial in the US.  

“We look forward to providing an update on Lupuzor's progress once Teva's acquisition of Cephalon is complete.  

“In parallel, we are focusing our own efforts on our promising cancer drug and are pleased to have seen encouraging results so far and to have achieved publication in the journal of the American Association for Cancer Research.  

“We look forward to building on this success during the rest of 2011 and in the coming years."

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.